Patents by Inventor Catherine C. Thompson
Catherine C. Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7416731Abstract: The novel nucleotide sequence and deduced amino acid sequence of the human Hairless gene and protein, respectively, are disclosed. A Hairless expression construct may be used in transcription assays. Moreover, processes of making and using the aforementioned products in screening assays which affect Hairless-regulated transcription are disclosed. Kits comprising a polynucleotide, polypeptide, specific binding molecule, or combinations thereof are disclosed.Type: GrantFiled: July 18, 2005Date of Patent: August 26, 2008Assignee: The Carnegie Institution of WashingtonInventor: Catherine C. Thompson
-
Patent number: 6984495Abstract: The novel nucleotide sequence and deduced amino acid sequence of the human Hairless gene and protein, respectively, are disclosed. A Hairless expression construct may be used in transcription assays. Moreover, processes of making and using the aforementioned products in screening assays which affect Hairless-regulated transcription are disclosed. Kits comprising a polynucleotide, polypeptide, specific binding molecule, or combinations thereof are disclosed.Type: GrantFiled: December 21, 2001Date of Patent: January 10, 2006Assignee: Carnegie Institution of WashingtonInventor: Catherine C. Thompson
-
Patent number: 6806359Abstract: The present invention provides substantially pure DNA's comprised of sequences which encode proteins having the hormone-binding and/or transcription-activating characteristics of a glucocorticoid receptor, a mineralocorticoid receptor, or a thyroid hormone receptor. The invention also provides various plasmids containing receptor sequences which exemplify the DNA's of the invention. The invention further provides receptor proteins, including modified functional forms thereof, expressed from the DNA's (or mRNA's) of the invention. In addition to novel receptor DNA, RNA and protein compositions, the present invention involves a bioassay for determining the functionality of a receptor protein. By using our bioassay system we have discovered that a necessary and sufficient condition for activation of transcription of a gene (G), whose transcription is activated by hormones complexed with receptors, is the presence of the hormone and its receptor in the cell (C) where (G) is located.Type: GrantFiled: June 5, 1995Date of Patent: October 19, 2004Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 6794160Abstract: The present invention provides substantially pure DNA's comprised of sequences which encode proteins having the hormone-binding and/or transcription-activating characteristics of a glucocorticoid receptor, a mineralocorticoid receptor, or a thyroid hormone receptor; various plasmids containing receptor sequences which exemplify these DNA's; receptor proteins, including modified functional forms thereof, expressed from these DNA's (or mRNA's); and a bioassay for determining the functionality of a receptor protein. Use of this bioassay has led to the discovery that a necessary and sufficient condition for activation of transcription of a gene (G), whose transcription is activated by hormones complexed with receptors, is the presence of the hormone and its receptor cell (C) where (G) is located. As a result, two new methods for producing desired proteins in genetically engineered cells were discovered.Type: GrantFiled: June 5, 1995Date of Patent: September 21, 2004Inventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Publication number: 20030027300Abstract: The novel nucleotide sequence and deduced amino acid sequence of the human Hairless gene and protein, respectively, are disclosed. A Hairless expression construct may be used in transcription assays. Moreover, processes of making and using the aforementioned products in screening assays which affect Hairless-regulated transcription are disclosed. Kits comprising a polynucleotide, polypeptide, specific binding molecule, or combinations thereof are disclosed.Type: ApplicationFiled: December 21, 2001Publication date: February 6, 2003Applicant: Carnegie Institution of WashingtonInventor: Catherine C. Thompson
-
Patent number: 6348348Abstract: The novel nucleotide sequence and deduced amino acid sequence of the human Hairless gene and protein, respectively, are disclosed. A Hairless expression construct may be used in transcription assays. Moreover, processes of making and using the aforementioned products in screening assays which affect Hairless-regulated transcription are disclosed. Kits comprising a polynucleotide, polypeptide, specific binding molecule, or combinations thereof are disclosed.Type: GrantFiled: April 7, 1999Date of Patent: February 19, 2002Assignee: The Carnegie Institution of WashingtonInventor: Catherine C. Thompson
-
Patent number: 5606021Abstract: The present invention provides recombinant proteins having the hormone-binding and/or transcription-activating characteristics of a mineralocorticoid receptor. The invention also provides proteins expressed from recombinant DNA encoding a naturally occurring receptor having the hormone-binding and/or transcription-activating characteristics of a mineralocorticoid receptor.Type: GrantFiled: December 17, 1993Date of Patent: February 25, 1997Assignee: The Salk Institute For Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 5599904Abstract: A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand-(e.g.Type: GrantFiled: March 3, 1992Date of Patent: February 4, 1997Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere
-
Patent number: 5597705Abstract: The present invention provides a recombinant expression system for production of functional thyroid hormone receptor protein(s). The invention also provides a method to produce thyroid hormone receptor protein(s) by culturing the cells of the invention recombinant expression system. Also provided are thyroid hormone receptor protein(s) produced by the invention method. In addition, the present invention provides recombinant DNAs comprised of sequences which encode proteins having the hormone-binding and/or transcription-activating characteristics of a thyroid hormone receptor. The invention also provides various plasmids containing receptor sequences which exemplify the DNAs of the invention. The invention further provides complementary mRNAs, cells transformed with invention DNAs, and nucleic acid probes derived from invention DNAs.Type: GrantFiled: December 10, 1993Date of Patent: January 28, 1997Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 5571692Abstract: DNA encoding a human retinoic acid receptor alpha protein is disclosed. The sequence of the receptor is encoded by the cDNA insert of plasmid phRAR1, which has been deposited with ATCC. Methods employing chimeric receptors derived from the retinoic acid receptor are illustrated which demonstrate that the ligand for the new receptor is the retinoid, retinoic acid.Type: GrantFiled: December 16, 1993Date of Patent: November 5, 1996Assignee: The Salk Institute For Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere
-
Patent number: 5548063Abstract: A human retinoic acid receptor alpha protein is disclosed. The receptor is encoded by the cDNA insert of plasmid phRAR1, which has been deposited with ATCC. Methods employing chimeric receptors derived from the retinoic acid receptor are illustrated which demonstrate that the ligand for the new receptor is the retinoid, retinoic acid.Type: GrantFiled: January 11, 1994Date of Patent: August 20, 1996Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere
-
Patent number: 5534418Abstract: The present invention provides methods for the controlled production of recombinant proteins in cells. Cells employed in the invention method contain a gene encoding the desired recombinant protein, with transcription of the gene maintained under the control of a transcriptional control element which is activated by a ligand/receptor complex. The ligand/receptor complex is formed when a ligand (which is a hormone or/and analog thereof) is complexed with a receptor (which is a hormone receptor or functional analog thereof which has the transcription activating properties of the receptor). Receptor is produced by the expression of non-endogenous DNA which is also present in the cells used for production of recombinant protein.Type: GrantFiled: December 10, 1993Date of Patent: July 9, 1996Assignee: The Salk Institute for Biological StudiesInventors: Roland M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 5312732Abstract: The present invention provides substantially pure DNA's comprised of sequences which encode proteins having the hormone-binding and/or transcription-activating characteristics of a glucocorticoid receptor, a mineralocorticoid receptor, or a thyroid hormone receptor. The invention also provides various plasmids containing receptor sequences which exemplify the DNA's of the invention. The invention further provides receptor proteins, including modified functional forms thereof, expressed from the DNA's (or mRNA's) of the invention. In addition to the novel receptor DNA, RNA and protein compositions, the present invention involves a bioassay for determining the functionality of a receptor protein. By using our bioassay system we have discovered that a necessary and sufficient condition for activation of transcription of a gene (G), whose transcription is activated by hormones complexed with receptors, is the presence of the hormone and its receptor in the cell (C) where (G) is located.Type: GrantFiled: March 7, 1991Date of Patent: May 17, 1994Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 5274077Abstract: A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by CDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand--(e.g.Type: GrantFiled: November 13, 1992Date of Patent: December 28, 1993Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere
-
Patent number: 5171671Abstract: A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand-(e.g.Type: GrantFiled: August 6, 1990Date of Patent: December 15, 1992Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Uemsono, Vincent Giguere
-
Patent number: 5071773Abstract: The present invention discloses two hormone receptor-related bioassays. The first bioassay is useful for determining whether a protein suspected of being a hormone receptor has transcription-activating properties of a hormone receptor. The second bioassay is useful for evaluating whether compounds are functional ligands for receptor proteins. According to the first bioassay, cells that contain non-endogenous DNA which expresses a protein suspected of being a hormone receptor and which contain a DNA sequence encoding an operative hormone responsive promoter/enhancer element linked to an operative reporter gene, are cultured, the culturing being conducted in a culture medium containing a known hormone, or an analog thereof. The cultured cells are then monitored for induction of the product of the reporter gene as an indication of functional transcription-activating binding between the hormone or hormone analog and the protein suspected of being a hormone receptor.Type: GrantFiled: October 20, 1987Date of Patent: December 10, 1991Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 4981784Abstract: A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand-(e.g.Type: GrantFiled: November 30, 1988Date of Patent: January 1, 1991Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere